UF researchers create cancer-targeting compound

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of University of Florida medicinal chemists and cancer biologists has created a chemical compound that selectively helps cells dispose of proteins that cause cancer cells to grow.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA approved Tuksya (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive breast cancer following induction treatment. The approval expands the use of Tuksya to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login